Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZINCS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2023232144A1ADC44
|
|||||
| Synonyms |
WO2023232144A1ADC44
Click to Show/Hide
|
|||||
| Organization |
CANWELL BIOTECH LIMITED
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
5.68
|
|||||
| Structure |
|
|||||
| Antibody Name |
Atezolizumab
|
Antibody Info | ||||
| Antigen Name |
Programmed cell death 1 ligand 1 (CD274)
|
Antigen Info | ||||
| Payload Name |
WO2025015586A1, ADC35, Payload
|
Payload Info | ||||
| Therapeutic Target |
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
|
Target Info | ||||
| Linker Name |
SMCC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
(1r,4r)-N- (2- ((2- ((4- ((4-amino-2-butyl-7- (dimethylphosphoryl)-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)- 4- ((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)-N-methylcyclohexane-1-carboxamide
|
|||||